Literature DB >> 18405984

Immuno stimulating glycophosphosphingolipid antigen from Leishmania donovani is recognized by visceral leishmaniasis patient sera.

Siddhartha Kumar Bhaumik1, Manoj Kumar Singh, Subir Karmakar, Tripti De.   

Abstract

Surface antigens on Leishmania promastigotes and infected macrophages are obvious targets in immunoprophylaxis for leishmanial infection. The glycophosphosphingolipid (GSPL) antigen isolated from Leishmania donovani surface membrane was recognized by sera from patients with visceral leishmaniasis. GSPL was also expressed on the membrane of parasite-infected macrophages. The effect of GSPL on the production of reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI) was studied using the macrophage cell line J774.1. In addition, induction of IFNgamma, IL4, IL10, IL12 secretion in presence of GSPL was investigated in PBMC from normal individuals. ROS and RNI in addition to IFNgamma and IL12 were induced by GSPL. Though there was a moderate induction of IL10, there was very little induction of the Th2 cytokine IL4. GSPL also induced blood cells to proliferate. The data suggests that this functionally important antigen of L. donovani may be used as a candidate vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405984     DOI: 10.1016/j.molbiopara.2008.03.001

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  2 in total

1.  Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased β1-integrin signaling and delayed wound repair.

Authors:  Yutaka Itokazu; Richard E Pagano; Andreas S Schroeder; Scott M O'Grady; Andrew H Limper; David L Marks
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-05       Impact factor: 4.249

2.  TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis.

Authors:  Subir Karmakar; Siddhartha Kumar Bhaumik; Joydeep Paul; Tripti De
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.